info@nsiv.org
North Shore InnoVenturesNorth Shore InnoVenturesNorth Shore InnoVenturesNorth Shore InnoVentures
  • Home
  • About NSIV
    • What Is
    • Impact
    • Our Team
    • Board of Directors
  • Incubation
    • Facilities
    • Equipment
    • Programs
  • Companies & Community
    • Incubated Companies
    • Resources
      • Jobs
      • Post a Job
      • Manage Job Listings
    • Our Sponsors
  • News & Events
  • Get Involved
    • Sponsorship
    • Mentorships
    • Internships
    • Join the Staff
  • Contact
Next Previous

NSIV Member Spotlight – Cellanyx

26 June, 2019

For years oncology practice has continued to both over- and under- treat cancer patients. Though not always mistreated, aggressive and indolent cancers are difficult for clinicians to distinguish between. Therefore, the treatment decision is often left to the preference of the patient. Cellanyx has developed a cutting-edge solution by combining two of the most exciting technologies in medical science: single cell analysis and machine learning/AI.

Traditionally, scientists analyze dead tumor cells from a biopsy. Alternatively, Cellanyx studies the behaviors of live tumor cells. This uncovers how aggressive or abnormal the tumor cells are because, as CEO Guy L. Fish explains, “live tumor cells don’t lie.” The tumor cells are cultured proprietary extracellular matrices that do not alter their behaviors or markers. Cellanyx’ technology tracks thousands of cells and hundreds of markers per cell at once, over multiple time periods, for one tumor sample. Millions of measurements of cell behaviors are then analyzed by machine learning algorithms. Cellanyx’ most recent work revolves around prostate cancer treatment decisions since the traditional risk assessment test is only 65% accurate. Cellanyx’ predictive metrics has an overall accuracy of 88% (specificity = 92%) which is significantly higher than any current prostate test.

This is great news for the 250,000 prostate cancer patients each year who are forced to make treatment decisions without adequate information. Cellanyx’ ability to observe the living cells opens the door for major improvements in assessing the appropriate treatment for patients with prostate cancer, bladder, breast, and renal cancers. Many patients have indolent cancer cells that could be watched for years without needing treatment. Patients could avoid a lot of costs, side effects, and complications if doctors can identify the tumors as indolent.

A part of Cellanyx’ recent success is thanks to the addition of a new management team which includes Guy L. Fish, MD, MBA as Cellanyx’ CEO as of February 2019. With his 30 years of expertise, “Guy brings an enormous breadth of experience in clinical practice as well as healthcare strategy that spans new technology assessment, business development, fund raising and commercialization for emerging biotechnology companies” remarked Board Chairman Dr. Pravin Chaturvedi. The new management team is focused on advancing commercial operations and increasing funding. Their goal is to establish a commercial laboratory in the second half of 2020. With this progress, Cellanyx is on track to be commercial and able to take patient specimens under fee for service beginning early 2021.

Leave a Comment

Cancel reply

Your email address will not be published. Required fields are marked *

NSIV
100 Cummings Center
Suite 451C
Beverly, MA | 01915

Tour our facilities and be sure to ask about our cutting-edge equipment.

Schedule Now

Post Archive

  • July 2022 (1)
  • June 2022 (1)
  • May 2022 (1)
  • April 2022 (1)
  • February 2022 (1)
  • January 2022 (2)
  • November 2021 (1)
  • October 2021 (1)
  • September 2021 (1)
  • August 2021 (1)
  • July 2021 (1)
  • June 2021 (1)
  • May 2021 (1)
  • April 2021 (1)
  • March 2021 (1)
  • January 2021 (3)
  • December 2020 (1)
  • November 2020 (1)
  • October 2020 (1)
  • September 2020 (1)
  • August 2020 (1)
  • June 2020 (5)
  • May 2020 (1)
  • April 2020 (3)
  • January 2020 (1)
  • November 2019 (2)
  • October 2019 (1)
  • September 2019 (1)
  • August 2019 (1)
  • July 2019 (1)
  • June 2019 (2)
  • May 2019 (2)
  • April 2019 (2)
  • March 2019 (2)
  • February 2019 (2)
  • January 2019 (2)
  • November 2018 (2)
  • October 2018 (5)
  • August 2018 (3)
  • July 2018 (4)
  • June 2018 (3)
  • May 2018 (2)
  • April 2018 (4)
  • March 2018 (5)
  • February 2018 (2)
  • January 2018 (6)
  • December 2017 (2)
  • November 2017 (6)
  • October 2017 (4)
  • September 2017 (1)
  • August 2017 (1)
  • July 2017 (1)
  • June 2017 (1)
  • May 2017 (2)
  • April 2017 (3)
  • March 2017 (4)
  • February 2017 (2)
  • January 2017 (1)
  • December 2016 (1)
  • October 2016 (1)
  • September 2016 (2)
  • August 2016 (4)
  • July 2016 (1)
  • June 2016 (7)
  • May 2016 (4)
  • April 2016 (2)
  • March 2016 (6)
  • February 2016 (6)
  • January 2016 (3)
  • November 2015 (4)
  • October 2015 (2)
  • September 2015 (3)
  • August 2015 (2)
  • July 2015 (1)
  • June 2015 (8)
  • March 2015 (1)
  • February 2015 (2)
  • January 2015 (2)
  • December 2014 (2)
  • November 2014 (4)
  • October 2014 (5)
  • September 2014 (3)
  • August 2014 (3)
  • July 2014 (2)
  • June 2014 (6)
  • May 2014 (5)
  • April 2014 (3)
  • March 2014 (7)
  • January 2014 (4)
  • December 2013 (2)
  • November 2013 (2)
  • October 2013 (6)
  • September 2013 (1)
  • August 2013 (1)
  • July 2013 (1)
  • June 2013 (3)
  • May 2013 (2)
  • April 2013 (8)
  • March 2013 (4)
  • February 2013 (4)
  • January 2013 (3)
  • December 2012 (8)
  • November 2012 (7)
  • October 2012 (6)
  • September 2012 (15)
  • August 2012 (5)
  • July 2012 (4)
  • June 2012 (1)
  • January 2012 (2)

  • You may also like

    North Shore InnoVentures receives $200K+ EDA Grant

    Read now
  • You may also like

    Entrepreneur U: Smart Marketing for Emerging Companies

    Read now
  • You may also like

    Clean Energy Alliance Announces Award to North Shore InnoVentures from DOE-CEA Partnership

    Read now
  • You may also like

    Innoventures U: The Ins and Outs of Technology Licensing

    Read now
  • You may also like

    NSIV Grad Making More News

    Read now
  • You may also like

    July’s Innoventures U – A Great Primer on Tech Licensing

    Read now
  • You may also like

    BIVC Highlighted

    Read now
  • You may also like

    Next Innoventures U: August 16

    Read now

North Shore InnoVentures
100 Cummings Center
Suite 451C
Beverly, MA | 01915
978-867-0600

Apply for Incubation Space

Interested in incubating your company with NSIV? Submit your application today!

APPLY FOR A SPACE

Stay in the Know

Copyright 2017 © North Shore InnoVentures Inc. | All Rights Reserved | info@nsiv.org
  • Home
  • About NSIV
    • What Is
    • Impact
    • Our Team
    • Board of Directors
  • Incubation
    • Facilities
    • Equipment
    • Programs
  • Companies & Community
    • Incubated Companies
    • Resources
      • Jobs
      • Post a Job
      • Manage Job Listings
    • Our Sponsors
  • News & Events
  • Get Involved
    • Sponsorship
    • Mentorships
    • Internships
    • Join the Staff
  • Contact
North Shore InnoVentures